期刊文献+

绝经后2型糖尿病患者LDL/HDL比值与骨强度以及骨折风险的相关性研究 被引量:7

Relationship between LDL/HDL ratio and stiffness index and fracture risk in postmenopausal women with type 2 diabetes mellitus
下载PDF
导出
摘要 目的探讨LDL/HDL比值与绝经后女性2型糖尿病患者骨强度以及骨折风险的相关性。方法选取2014年1月至2018年1月在我院内分泌科就诊的女性2型糖尿病(type 2 diabetes mellitus,T2DM)患者226例,其中113例已绝经,将患者分为未绝经组与已绝经组。运用超声骨密度仪(QUS)分别测量受试者的骨强度指数(stiffness index,SI),同时收集患者一般资料如年龄、体质量指数(bone mass index,BMI)、糖尿病病程等,测定血脂、糖化血红蛋白、骨钙素(BGP)、血清Ⅰ型原胶原N-端前肽(PINP)、血清1型胶原交联β-C-末端肽(β-CTX),并计算TC/HDL比值(THR)、LDL/HDL比值(LHR)。采用骨折风险预测工具模型(FRAX)计算患者10年任何重要部位骨质疏松性骨折(PMOF)、髋部骨折(PHF)概率。采用线性回归分析不同血脂指标与SI相关性,进一步评估LHR与骨代谢、PMOF和PHF等的相关关系。结果(1)与未绝经组相比,已绝经组SI[(79.96±11.35)VS(92.50±15.95),P<0.001)]、BGP[(13.47±4.11)VS(21.00±10.90),P=0.039)]、PINP [(34. 59±16.16)VS(56.70±37.33),P=0.016]降低,β-CTX[(590. 71±263. 24) VS (423. 07±198. 04),P=0. 021]、LHR[(2.16±0.76)VS (1.89±0.81),P=0.040)]、PMOF[(3.67±1.28)VS(1. 50±0.14),P=0.009]、PHF[(1.44±0.61)VS(0.65±0.12),P=0.005]升高,差异有统计学意义;(2) Pearson相关性分析结果提示SI与PMOF、PHF呈负相关(β=-0. 749;β=-0. 681,P均<0.001);(3)分别校正年龄与BMI(β=-0. 245,P=0. 006),Hba1c与病程(β=-0. 240,P=0. 009),年龄、BMI、Hba1c、病程和肌酐(β=-0. 248,P=0. 005),绝经后2型糖尿病患者LHR与SI均有显著负相关;(4)LHR与PMOF、PHF、β-CTX呈正相关(β=0. 336;β=0. 319;β=277,P均<0.05),与BGP、PINP呈负相关(β=-0. 310;β=-0. 298,P均<0.05)。结论绝经后2型糖尿病患者LHR与SI、FRAX骨折风险评分以及骨代谢指标相关,高LHR可能引起SI下降、骨折风险增高,其机制可能与成骨减少、破骨增加有关。 Objective To study the relationship between LDL/HDL ratio(LHR) and stiffness index and fracture risk in postmenopausal women with type 2 diabetes mellitus(T2DM). Methods From 2014 to 2017,in the Endocrinology Department of Anhui Provincial Hospital a total of 113 postmenopausal women with T2DM were selected as the postmenopausal group,and 113 premenopausal women with T2DM were selected as the premenopausal group. Bone strength index(SI) based on QUS were measured.General information such as age and body mass index(BMI),T2DM history,blood lipids,glycosylated hemoglobin(HbA1c),osteocalcin(BGP),serum type Ⅰ procollagen N-terminal propeptide(PINP),serum type 1 collagen cross-linking β-C-terminal peptide(β-CTX),and calculation of TC/HDL ratio(THR) and LDL/HDL ratio(LHR) of the two groups were record and compared.Fracture Risk Assessment Tool(FRAX) was utilized to estimate the 10-year probability of a major osteoporotic fracture(PMOF) and the probability of hip fracture(PHF). Linear regression analysis was used to analyze the correlation between different blood lipids and SI,and evaluate the relationship between LHR and bone metabolism, PMOF and PHF. Results(1) Compared with the premenopausal group,the postmenopausal group had significantly lower SI [(79. 96±11. 35) VS(92. 50±15. 95),P<0. 001],BGP[(13. 47±4. 11) VS(21. 00±10. 90),P = 0. 039],PINP [(34. 59±16. 16) VS(56. 70±37. 33),P = 0. 016],and significantly higher β-CTX [(590. 71±263. 24) VS(423. 07 ± 198. 04),P = 0. 021],LHR [(2. 16 ± 0. 76) VS(1. 89 ± 0. 81),P = 0. 040],PMOF [(3. 67± 1. 28) VS(1. 50 ± 0. 14),P = 0. 009] and PHF [(1. 44 ± 0. 61) VS(0. 65 ± 0. 12),P = 0. 005].(2) Pearson correlation analysis showed that SI was negatively correlated with PMOF and PHF(β =-0. 749;β =-0. 681,both P<0. 001).(3) In models adjusted age,BMI,HbA1c,duration of diabetes and Cr,a negative association was found between LHR and SI(β =-0. 248,P = 0. 005).(4) Regression analyses showed that LHR was positively associated with PMOF,PHF and β-CTX(β = 0. 336;β
作者 黄斌 宁珂 陈超 叶山东 HUANG Bin;NING Ke;CHEN Chao;YE Shandong(Department of Endocrinology,The First Affiliated Hospital of University of Science and Technology of China,Anhui Provincial Hospital,Hefei 230001,China)
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2020年第2期181-185,共5页 Chinese Journal of Osteoporosis
基金 安徽省卫生厅医学科研课题项目(13ZC003)
关键词 2型糖尿病 绝经后 LDL/HDL值 骨强度指数 骨折风险 骨代谢标志物 type 2 diabetes mellitus postmenopausal women LDL/HDL ratio SI fracture risk bone turnover markers
  • 相关文献

参考文献5

二级参考文献105

  • 1吴宜勇,惠英,邓文慧,周钱,李燕春.盐酸雷洛昔芬防治绝经后骨质疏松症随机双盲对照研究[J].中国新药杂志,2004,13(8):741-744. 被引量:2
  • 2ZHANGJun , GE Ning, HUANG Xiao-li, et al. Review of drug treatment for osteoporosis. ChineseJournal of practical internal medicine, 2006, 26(4): 313-315. 被引量:1
  • 3Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N EnglJ Med,1997 ,337:1641-1647. 被引量:1
  • 4JohnstonJr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo controlled trials. Arch Intern Med ,2000,160 :3444-3450. 被引量:1
  • 5Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifane , results from a 3 -year randomized clinical trial.JAMA, 1999 ,282 :637-645. 被引量:1
  • 6Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene . a randomized trial.J Bone Miner Res,1998,J3:1747-1754. 被引量:1
  • 7Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int, 1999, 10 :330-336. 被引量:1
  • 8Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density! serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N EnglJ Med,1997 ,337:1641-1647. 被引量:1
  • 90Johnell, WH Scheek, Y Lu, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in ostmenopausal women with osteoporosis.J Clin Endocrinol Metab, 2002,87 :985-992. 被引量:1
  • 10Morii H, Ohashi Y, Taketani Y, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover inJapanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int,2003,4 :793- 800. 被引量:1

共引文献241

同被引文献49

引证文献7

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部